Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Alpers

Gastroenterology Saint Louis, MO Medical Doctor

NPI 1740207208 CMS profile 123867

4921 Parkview Pl, Div Im Gastroenterology, Ste 8C, Saint Louis, MO 63110

Open in the dashboard

General payments

$616,196

248 records reported · program years 2019–2025

Research payments

$24,350

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Alpers of Saint Louis, MO is reported in the CMS Open Payments database as having received $616,196 across 248 general payments and $24,350 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,050 28
2024 General $50,038 16
2023 General $66,538 27
2023 Research $18,600 3
2022 General $77,339 36
2021 General $111,879 47
2021 Research $1,925 1
2020 General $119,555 43
2020 Research $3,825 1
2019 General $163,798 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Alpers
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to David Alpers were reported at $27,050. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year David Alpers Gastroenterology median Middle half National median
2019 $163,798 $417 $126–$1,100 $163
2020 $119,555 $224 $74–$624 $114
2021 $111,879 $352 $106–$1,054 $132
2022 $77,339 $448 $129–$1,270 $149
2023 $66,538 $533 $150–$1,390 $160
2024 $50,038 $605 $160–$1,606 $164
2025 $27,050 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $206,040 65 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $193,468 85 payments
  3. GlaxoSmithKline, LLC. $122,514 34 payments
  4. Pfizer Inc. $75,460 21 payments
  5. Alexion Pharmaceuticals, Inc. $12,714 20 payments
  6. Madrigal Pharmaceuticals $6,000 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $609,211 232 payments
  2. Travel and Lodging $5,993 12 payments
  3. Food and Beverage $993 4 payments
Products named General payments · program years 2019–2025
  1. SAMSCA $104,268 21 payments
  2. TOLVAPTAN $99,982 57 payments
  3. JYNARQUE $16,918 8 payments
  4. REZDIFFRA $6,000 23 payments
  5. TAKHZYRO $1,200 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $20,525 4 payments
  2. Alexion Pharmaceuticals, Inc. $3,825 1 payment

Records

253 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record